The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma

被引：0
|
作者：
Perry, J. R.
Mason, W. P.
Belanger, K.
Kavan, P.
Fulton, D.
Easaw, J.
Kirby, S.
Macdonald, D.
Shields, C.
Pouliot, J.
机构：
[1] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Hop Notre Dame de Bon Secours, Montreal, PQ H2L 4K8, Canada
[4] Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada
[5] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[6] Tom Baker Canc Clin, Calgary, AB, Canada
[7] QE II Hlth Sci Ctr, Halifax, NS, Canada
[8] London Reg Canc Program, London, ON, Canada
[9] Hop Enfants Jesus, Quebec City, PQ, Canada
[10] Schering Plough Canada, Kirkland, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2010
引用
收藏
页数：1
相关论文
共 25 条
  • [21] BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial
    Burri, Stuart H.
    Prabhu, Roshan S.
    Sumrall, Ashley L.
    Brick, Wendy
    Blaker, Brian D.
    Heideman, Brent E., Jr.
    Boltes, Peggy
    Kelly, Renee
    Symanowski, James T.
    Wiggins, Walter F.
    Ashby, Lynn
    Norton, H. James
    Judy, Kevin
    Asher, Anthony L.
    JOURNAL OF NEURO-ONCOLOGY, 2015, 123 (02) : 259 - 266
  • [22] A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo)astrocytoma: An interim analysis of toxicity.
    Neyns, B
    van Mierlo, B
    Menten, J
    Dhondt, L
    Joosens, E
    Vastesaeger, N
    Branle, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 129S - 129S
  • [23] A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion
    La Rocca, R. V.
    Hodes, J.
    Villanueva, W. G.
    Vitaz, T. W.
    Morassutti, D. J.
    Doyle, M. J.
    Glisson, S.
    Cervera, A.
    Stribinskiene, L.
    New, P.
    Litofsky, N. S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 445 - 445
  • [24] A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients (pts) with newly diagnosed supratentorial high grade malignant glioma (MG) who have undergone surgery with carmustine (BCNU) wafer insertion.
    Larocca, RV
    Vitaz, TW
    Morassutti, DJ
    Doyle, MJ
    Glisson, SD
    Hargis, JB
    Goldsmith, GH
    Cervera, A
    Stribinskiene, L
    New, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 125S - 125S
  • [25] A PHASE1/2 CLINICAL TRIAL OF VELIPARIB (ABT-888) AND RADIATION FOLLOWED BY MAINTENANCE THERAPY WITH VELIPARIB AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A PEDIATRIC BRAIN TUMOR CONSORTIUM INTERIM REPORT OF PHASE II STUDY
    Baxter, Patricia
    Su, Jack
    Li, Xiao-nan
    Thomas, Arzu Onar
    Billups, Catherine
    Thompson, Patrick
    Poussaint, Tina
    McKeegan, Evelyn
    Wan, Xia
    Ansell, Peter
    Giranda, Vincent
    Paulino, Arnold
    Kilburn, Lindsay
    Qaddoumi, Ibrahim
    Broniscer, Alberto
    Blaney, Susan
    Boyett, James
    Fouladi, Maryam
    NEURO-ONCOLOGY, 2016, 18 : 27 - 27
123